Search research articles
Contact Us
Filters
Showing results (81-90 of 86) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 86 results.
Gynecologic Oncology
|
September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial
Edith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI
|
February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial
Dan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
The Journal of Infectious Diseases
|
October 5, 2013
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation
Anne Szarewski, S Rachel Skinner, Suzanne M Garland, et al.
The Journal of Infectious Diseases
|
March 11, 2014
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA
Xavier Castellsagué, Paulo Naud, Song-Nan Chow, et al.
The Lancet. Oncology
|
November 15, 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen, Jorma Paavonen, Cosette M Wheeler, et al.
Plos One
|
November 22, 2013
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study
Unnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 86) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 86 results.
Gynecologic Oncology
|
September 4, 2012
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial
Edith Roset Bahmanyar, Jorma Paavonen, Paulo Naud, et al.
Clinical and Vaccine Immunology : CVI
|
February 6, 2015
Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial
Dan Apter, Cosette M Wheeler, Jorma Paavonen, et al.
The Journal of Infectious Diseases
|
October 5, 2013
Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation
Anne Szarewski, S Rachel Skinner, Suzanne M Garland, et al.
The Journal of Infectious Diseases
|
March 11, 2014
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA
Xavier Castellsagué, Paulo Naud, Song-Nan Chow, et al.
The Lancet. Oncology
|
November 15, 2011
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen, Jorma Paavonen, Cosette M Wheeler, et al.
Plos One
|
November 22, 2013
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study
Unnop Jaisamrarn, Xavier Castellsagué, Suzanne M Garland, et al.
Page
of 9